These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2853070)

  • 1. Recovery from opioid receptor alkylation: social conflict analgesia and brain [3H]etorphine binding in beta-chlornaltrexamine-treated mice.
    Lazega D; Frischknecht HR; Waser PG; Siegfried B
    Eur J Pharmacol; 1988 Oct; 155(3):333-7. PubMed ID: 2853070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
    Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW
    Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine.
    Caruso TP; Larson DL; Portoghese PS; Takemori AE
    J Pharmacol Exp Ther; 1980 Jun; 213(3):539-44. PubMed ID: 6162947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone-induced opiate receptor supersensitivity.
    Zukin RS; Sugarman JR; Fitz-Syage ML; Gardner EL; Zukin SR; Gintzler AR
    Brain Res; 1982 Aug; 245(2):285-92. PubMed ID: 6289965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence and development of stress-induced analgesia and concomitant behavioral changes in mice exposed to social conflict.
    Frischknecht HR; Siegfried B
    Physiol Behav; 1988; 44(3):383-8. PubMed ID: 2851847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profiles of beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) on the mouse vas deferens preparation.
    Ward SJ; Portoghese PS; Takemori AE
    Eur J Pharmacol; 1982 Jun; 80(4):377-84. PubMed ID: 6286325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous development of opioid tolerance and opioid antagonist-induced receptor upregulation.
    Yoburn BC; Sierra V; Lutfy K
    Brain Res; 1990 Oct; 529(1-2):143-8. PubMed ID: 2178026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
    Portoghese PS; Larson DL; Jiang JB; Caruso TP; Takemori AE
    J Med Chem; 1979 Feb; 22(2):168-73. PubMed ID: 218009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment.
    Tao PL; Law PY; Loh HH
    J Pharmacol Exp Ther; 1987 Mar; 240(3):809-16. PubMed ID: 3031275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat.
    Bardo MT; Bhatnagar RK; Gebhart GF
    Brain Res; 1983 Dec; 289(1-2):223-34. PubMed ID: 6318895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [3H]-etorphine and [3H]-diprenorphine receptor binding in vitro and in vivo: differential effect of Na+ and guanylyl imidodiphosphate.
    Kurowski M; Rosenbaum JS; Perry DC; Sadée W
    Brain Res; 1982 Oct; 249(2):345-52. PubMed ID: 6291717
    [No Abstract]   [Full Text] [Related]  

  • 12. Estimation of opioid receptor agonist dissociation constants with beta-chlornaltrexamine, an irreversible ligand which also displays agonism.
    Leff P; Dougall IG
    Br J Pharmacol; 1988 Sep; 95(1):234-40. PubMed ID: 2851350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of selective 3H-chlornaltrexamine-bound complexes, possible opioid receptor components in brains of mice.
    Caruso TP; Larson DL; Portoghese PS; Takemori AE
    Life Sci; 1980 Dec; 27(22):2063-9. PubMed ID: 6259471
    [No Abstract]   [Full Text] [Related]  

  • 14. Opioid receptor binding characteristics of the non-equilibrium mu antagonist, beta-funaltrexamine (beta-FNA).
    Ward SJ; Fries DS; Larson DL; Portoghese PS; Takemori AE
    Eur J Pharmacol; 1985 Jan; 107(3):323-30. PubMed ID: 2984010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of delta receptor mediation of supraspinal opioid analgesia by in vivo protection against the beta-funaltrexamine antagonist effect.
    Sánchez-Blázquez P; Garzón J
    Eur J Pharmacol; 1989 Jan; 159(1):9-23. PubMed ID: 2565240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the affinity ligands 14-beta-chloroacetylnaltrexone and 14-beta-bromoacetamidomorphine on [3H]-dihydromorphine binding sites in rat brain.
    Reichman M; Dirksen R; Abood LG; Gala D
    Biochem Pharmacol; 1986 Nov; 35(22):3995-8. PubMed ID: 3022745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The potentiation effect of haloperidol on the binding of etorphine to brain membranes in acupuncture analgesia].
    Wang HH; Zhu YH; Xu SF
    Sheng Li Xue Bao; 1994 Aug; 46(4):313-9. PubMed ID: 7973821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of brain membranes containing a single type of opioid receptor highly selective for dynorphin.
    James IF; Chavkin C; Goldstein A
    Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7570-4. PubMed ID: 6130527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 14 beta-(Bromoacetamido)morphine irreversibly labels mu opioid receptors in rat brain membranes.
    Bidlack JM; Frey DK; Seyed-Mozaffari A; Archer S
    Biochemistry; 1989 May; 28(10):4333-9. PubMed ID: 2548575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid analgesia in the mouse: evidence for multiple receptors using beta-FNA.
    Sánchez-Blázquez P; Garzón J
    NIDA Res Monogr; 1986; 75():465-8. PubMed ID: 2828993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.